P/B
—
Annovis Bio
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
$51.6M
Market Cap • 10/9/2026
2008
(18 years)
Founded
2020
(6 years ago)
IPO
NYSE
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
51,6M
EV
32,8M
EV/Revenue
0
EV/EBITDA
-0,7
EV/EBIT
-0,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-125,5%
Total Yield
-125,5%
Payout
0%
Retained Earnings
-196,1M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
39,8%
CAGR Net Income 5Y
42,5%
CAGR EPS 5Y
8,1%
CAGR OCF 5Y
42,8%
Leverage
N.D./EBITDA
0,4
Debt/Equity
0%
Current Ratio
3,5
Quick Ratio
2,9
Interest Coverage
3116,5%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!